Bioregenx (BRGX) Total Current Liabilities (2021 - 2026)

Bioregenx's Total Current Liabilities history runs 6 years deep, the most recent figure standing at $4.0 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 5.38% year-over-year to $4.0 million in Q1 2026; TTM through Mar 2026 was $4.0 million, a 5.38% increase from a year earlier, with the FY2025 full-year figure at $4.1 million, up 11.92% from the prior year.
• Total Current Liabilities eased to $4.0 million in Q1 2026 per BRGX's latest filing, from $4.1 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $4.1 million in Q4 2025 and bottomed at $39112.0 in Q1 2023.
• The 5-year median for Total Current Liabilities is $3.5 million (2024), against an average of $2.6 million.
• Across the five-year window, Total Current Liabilities jumped 8553.83% in 2024 and climbed 5.38% in 2026, its largest moves.
• Year by year, Total Current Liabilities stood at $64880.0 in 2022, then jumped by 4195.9% to $2.8 million in 2023, then soared by 30.35% to $3.6 million in 2024, then gained by 11.92% to $4.1 million in 2025, then retreated by 1.93% to $4.0 million in 2026.
• Per Business Quant, the three latest BRGX Total Current Liabilities figures stand at $4.0 million (Q1 2026), $4.1 million (Q4 2025), and $3.9 million (Q3 2025).